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Abstract
Background: Selenoprotein S (SelS) protects the functional integrity of the endoplasmic reticulum
against the deleterious effects of metabolic stress. SEPS1/SelS polymorphisms have been involved
in the increased release of pro-inflammatory cytokines interleukin (IL)-1β, tumor necrosis factor
(TNF)-α and IL-6 in macrophages. We aimed at investigating the role of the SEPS1 variants
previously associated with higher plasma levels of these cytokines and of the SEPS1 haplotypes in
the susceptibility to develop immune-mediated diseases characterized by an inflammatory
component.
Results:  Six polymorphisms distributed through the SEPS1  gene (rs11327127, rs28665122,
rs4965814, rs12917258, rs4965373 and rs2101171) were genotyped in more than two thousand
patients suffering from type 1 diabetes, rheumatoid arthritis or inflammatory bowel diseases and
550 healthy controls included in the case-control study.
Conclusion: Lack of association of SEPS1 polymorphisms or haplotypes precludes a major role of
this gene increasing predisposition to these inflammatory diseases.
Background
The human gene SEPS1, located on chromosome
15q26.3, encodes selenoprotein S which participates in
the retro-translocation of misfolded proteins from the
endoplasmic reticulum (ER) to the cytosol for their degra-
dation [1]. This ER membrane protein functions in stress
responses to prevent the deleterious consequences of
accumulation of misfolded proteins, accumulation that
has been linked to immune and inflammatory processes
[2]. A study identified the strong association of the proxi-
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mal promoter SEPS1 polymorphism at -105G/A with cir-
culating levels of three pro-inflammatory cytokines,
interleukin (IL)-6, IL-1β and TNF-α [3]. Moreover, these
authors reported that the mutant variant significantly
reduced the promoter activity of the SEPS1  gene in
stressed HepG2 cells and that the suppression of this gene
by short interfering RNA increased the release of pro-
inflammatory cytokines in a macrophage cell line. A regu-
latory loop has been recently proposed whereby cytokines
stimulate the expression of SEPS1, which in turn dimin-
ishes cytokine production [4].
The murine homolog gene of the human SEPS1 is the
Tanis gene, which encodes a serum amyloid A receptor [5].
Acute phase serum amyloid A proteins (SAAs) are multi-
functional apolipoproteins produced in large amounts
during the acute phase of inflammation and also during
the development of chronic inflammatory diseases. SAAs
are involved in the pathogenesis of several chronic inflam-
matory diseases, such as rheumatoid arthritis (RA) [6-9],
multiple sclerosis (MS)[10] and inflammatory bowel dis-
eases (IBD) [11-13]. It is believed that locally synthesized
SAA by synovial cells in the inflamed joints acts as an
autocrine inducer of matrix metalloproteinase-1 and
causes extensive joint erosion [14].
Altogether these data point to the important role of
selenoprotein S mediating inflammation, and we aimed
at testing whether the SEPS1 gene was involved in the
development of inflammatory autoimmune complex dis-
eases. These are multifactorial traits influenced by both
genetic predisposing factors and environmental triggers.
The activation of SEPS1 expression by fasting in vivo and
by glucose-deprivation in vitro allowed its assignation to
the glucose-regulated protein family [5,15]. Furthermore,
a locus on 15q26, IDDM3, was described to increase sus-
ceptibility to type 1 diabetes, T1D [16,17]. Therefore, we
decide to test the SEPS1 polymorphisms for association
with diabetes risk in a cohort of Spanish T1D patients.
Additionally, we pursued to study two other autoimmune
diseases with an important inflammatory component,
rheumatoid arthritis and the inflammatory bowel dis-
eases, Crohn's disease (CD) and ulcerative colitis (UC).
Provided this candidate gene previously related with the
inflammatory response shows any influence on the
pathogenesis of these diseases, a new mechanistic tool for
treatment would be available.
Methods
Patients and controls
The study group consisted of 592 RA, 674 IBD and 311
T1D unrelated patients, consecutively recruited from one
centre, either Hospital Clínico San Carlos or Hospital
Ramón y Cajal (Madrid, Spain).
T1D patients (median age at onset 15 years) diagnosed
according to the criteria of the American Diabetes Associ-
ation (ADA), were insulin-dependent at the time to study.
RA diagnosis was established based on the American Col-
lege of Rheumatology (ACR) criteria [18] and samples
were previously genotyped for HLA-DRB1. Mean age at
onset was 54 ± 14 years; 61% of the patients carried the
shared epitope; 66% and 50% of the patients were posi-
tive for rheumatoid factor and for anti-cyclic citrullinated
peptide, respectively, and 32% of the patients presented
nodular disease.
Diagnosis of IBD patients was based on standard clinical,
radiologic, endoscopic and histologic criteria [19]. The
mean age at onset for UC patients was 38 years; 41% of
the patients presented pancolitis; 47% and 13% of the
patients suffered extraintestinal manifestations and colec-
tomy, respectively. CD patients were classified according
to the location of the lesions in ileal (L1, 48%), colonic
(L2, 16%), ileocolonic (L3, 32%) and upper gastrointesti-
nal tract (L4, 3%) and according to the disease behavior in
inflammatory (B1, 43%), stricturing (B2, 15%) and perfo-
rating (B3, 42%). Only 20% of the CD patients debuted
after the age of 40.
A group of 550 healthy unrelated subjects from Madrid
(mainly hospital employees and blood donors) were
selected as controls. Cases and controls were all white
Spanish subjects and were included in this study after
written informed consent. The Ethics Committee of Hos-
pital Clínico (Madrid) approved the study.
SEPS1 polymorphisms
The  SEPS1  polymorphisms (rs11327127, rs28665122,
rs4965814, rs12917258, rs4965373 and rs2101171) were
genotyped using TaqMan assays from Applied Biosystems
following manufacturer's suggestions and analyzed in an
ABI 7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Foster City, CA, USA). Their location is indicated by
the distance from the transcription start site: two of them
are in the promoter region; another two in intron 5;
rs4965373 depending of alternative splicing is either in
intron 6 or in the 3'UTR region; and the last one is down-
stream at 9707 (see Table 1).
Statistical Analysis
Allele and genotype frequencies in patients and controls
were compared by χ2 test or Fisher exact test when neces-
sary; p values were considered significant at a level of
<0.05. Odds ratio (OR) and p values were calculated using
a standard package (Epi Info v. 6.02, CDC, Atlanta, USA).
For an OR = 1.5, the statistical power of our cohorts
ranged from 80 – 95% depending on the specific poly-
morphism analyzed.BMC Genomics 2008, 9:329 http://www.biomedcentral.com/1471-2164/9/329
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Haplotypic frequencies were estimated using the Expecta-
tion-Maximization algorithm implemented in the Arle-
quin v2.000 software [20] with number of iterations set at
5000 and initial conditions at 50, with an epsilon value of
10-7.
Results and discussion
The present study investigates the influence of all SEPS1
variants previously correlated with increased pro-inflam-
matory cytokines levels (polymorphisms at -105G/A,
3705G/A and 5227C/T) and of the SEPS1 haplotypes on
predisposition to inflammatory complex diseases.
We first analyzed the functional SEPS1 promoter poly-
morphism at -105G/A and no significant differences in
genotypic frequencies were observed when healthy con-
trols were compared with patients suffering from T1D, RA
or IBD (Table 1). As two other variants (rs4965814 and
rs4965373) have been associated with high plasma
cytokine levels [3], we studied them in our cohorts, and
the distribution of genotypes followed the same pattern in
patients and in controls (Table 1).
We selected three additional polymorphisms along the
gene from those described by Curran et al [3] in order to
analyze the haplotypes inferred by applying the Expecta-
tion-Maximization algorithm implemented in the Arle-
quin software. No significant difference in haplotype
frequencies was observed after appropriate correction for
multiple testing in any diseased cohort (Table 2).
A direct functionality has been attributed to the SEPS1
promoter polymorphism at -105G/A, increasing plasma
levels of the aforementioned cytokines presumably due to
the disruption of an ER stress element (ERSE). Two other
tested variants have also been strongly related with the cir-
culating levels of the inflammatory cytokines [3]. In con-
trast, a recent report did not find consistent association of
this polymorphism with circulating levels of either IL-6 or
TNF-α [21]. We did not observe differences in the geno-
typic distribution of the SEPS1 polymorphisms analyzed
in Spanish cohorts between patients suffering from
autoimmune diseases with a clear inflammatory compo-
nent, like T1D, RA or IBD, and controls. The analysis of
SEPS1  haplotypic frequencies did not differ between
patients and healthy individuals either.
Given that evidences exist for the affected expression and
activity of some selenoproteins depending on sexual
dimorphism in mouse [22] and human [23], we decided
to check for a gender specific association of -105G/A
SEPS1  polymorphism with the autoimmune disorders
under study; however, we did not detect a gender-bias in
our results. No significant difference between sex-strati-
fied cohorts was found for any of the polymorphisms
studied (Table 3).
Table 1: Genotypic frequencies of the SEL-S polymorphisms in Spanish T1D, RA and IBD patients and controls.
T1D patients RA patients CD patients UC patients Controls
-538 SEPS1 rs11327127
TT 183 (59%) 212 (59%) 218(62%) 235 (62%) 306 (60%)
T delT 106 (34%) 127 (35%) 111 (32%) 124 (32%) 180 (35%)
delT delT 21 (7%) 20 (6%) 21 (6%) 22 (6%) 28 (5%)
-105 SEPS1 rs28665122
CC 216 (70%) 253 (70%) 253(73%) 274 (71%) 360 (72%)
CT 85 (27%) 92 (26%) 83 (24%) 100 (26%) 124 (25%)
TT 9 (3%) 14 (4%) 12 (3%) 11 (3%) 14 (3%)
SEPS1 3705 rs4965814
TT 195 (63%) 224 (62%) 215 (68%) 225 (64%) 334 (65%)
TC 103 (33%) 118 (33%) 82 (26%) 112 (32%) 161 (31%)
CC 12 (4%) 17 (5%) 19 (6%) 12 (4%) 20 (4%)
SEPS1 4283 rs12917258
CC 148 (48%) 150 (42%) 164 (46%) 165 (44%) 215 (42%)
CG 137 (44%) 163 (45%) 149 (42%) 173 (46%) 247 (48%)
GG 25 (8%) 46 (13%) 40 (11%) 38 (10%) 49 (10%)
SEPS1 5227 rs4965373
GG 145 (47%) 187 (52%) 182 (52%) 178 (48%) 246 (48%)
GA 127 (41%) 142 (40%) 136 (39%) 163 (43%) 220 (43%)
AA 38 (12%) 30 (8%) 33 (9%) 33 (9%) 43 (9%)
SEPS1 9707 rs2101171
TT 177 (57%) 218 (61%) 216 (61%) 223 (59%) 296 (58%)
TC 113 (37%) 130 (36%) 122 (34%) 138 (37%) 191 (37%)
CC 20 (6%) 11 (3%) 16 (5%) 17 (4%) 26 (5%)BMC Genomics 2008, 9:329 http://www.biomedcentral.com/1471-2164/9/329
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SEPS1 expression was not significantly altered in intesti-
nal epithelial cells of IBD murine models or in intestinal
biopsies from IBD patients when compared with that
present in controls [24]. Concordantly, a study testing the
association of the promoter variant at -105 with cerebrov-
ascular disease found no influence on stroke risk [25].
Both studies are in agreement with our results that
showed lack of association between SEPS1  polymor-
phisms and susceptibility to chronic inflammatory dis-
eases. Moreover, a Finnish study of five variants in the
SEPS1  gene locus showed no significant difference
between carriers/non-carriers when cardiovascular cases
Table 2: Haplotypes estimated within the SEPS1 gene (alleles at -538/-105/3705/4283/5227/9707) and their distribution in patients and 
healthy individuals.
T1D (2n = 620) RA (2n = 718) CD (2n = 582) UC (2n = 664) Controls (2n = 982)
Freq. HT Freq. HT Freq. HT Freq. HT Freq. HT
TCTGGT 0.28827 179 0.32557 234 0.334699 195 0.339168 225 0.325571 320
TCTCGT 0.1716 106 0.1711 123 0.185524 108 0.176243 117 0.171104 168
TCTCAC 0.16575 103 0.15691 113 0.140554 82 0.161364 107 0.156905 154
DelT TCCGT 0.13375 83 0.12057 87 0.124047 72 0.122667 81 0.120574 118
DelT CTCAC 0.06887 43 0.07503 54 0.063144 37 0.051819 34 0.075028 74
TCTCAT 0.07046 44 0.05216 37 0.069939 41 0.060517 40 0.052158 51
TCCCGT 0.02949 18 0.02635 20 0.027632 16 0.027826 18 0.026349 26
TTCCGT 0.01231 8 0.01671 12 0.011366 7 0.010658 7 0.018029 18
DelT CCCGT 0.00875 5 0.01114 8 0.019499 11 0.015959 11 0.015536 15
Others 0.05075 31 0.04178 30 0.023596 13 0.033779 24 0.038746 38
Table 3: Genotype frequencies of SEPS1 polymorphisms in Spanish patients stratified by gender.
T1D 
Women 
(n, %)
T1D Men 
(n, %)
RA Women 
(n, %)
RA Men 
(n, %)
CD Women 
(n, %)
CD Men 
(n, %)
UC Women 
(n, %)
UC Men 
(n, %)
-538 SEPS1 
rs11327127
TT 90 (58) 93 (60) 160 (59) 49 (60) 108 (60) 109 (64) 97 (64) 135 (60)
T delT 53 (34) 53 (34) 100 (37) 24 (30) 61 (34) 50 (30) 49 (33) 72 (32)
delT delT 12 (8) 9 (6) 12 (4) 8 (10) 10 (6) 10 (6) 4 (3) 18 (8)
-105 SEPS1 
rs28665122
CC 107 (69) 109 (70) 191 (70) 58 (71) 128 (72) 123 (73) 106 (71) 160 (71)
CT 43 (28) 42 (27) 70 (26) 20 (25) 44 (25) 38 (23) 42 (28) 56 (25)
TT 5 (3) 4 (3) 11 (4) 3 (4) 5 (3) 7 (4) 2 (1) 9 (4)
SEPS1 3705 
rs4965814
TT 99 (64) 96 (62) 172 (63) 49 (60) 109 (68) 104 (68) 92 (69) 129 (62)
TC 50 (32) 53 (34) 87 (32) 28 (35) 43 (27) 40 (26) 38 (29) 70 (34)
CC 6 (4) 6 (4) 13 (5) 4 (5) 8 (5) 10 (6) 3 (2) 9 (4)
SEPS1 4283 
rs12917258
CC 82 (53) 66 (43) 109 (40) 39 (48) 78 (43) 84 (50) 69 (47) 92 (41)
CG 61 (39) 76 (49) 124 (46) 35 (43) 85 (47) 63 (37) 59 (40) 113 (51)
GG 12 (8) 13 (8) 39 (14) 7 (9) 17 (9) 23 (13) 20 (13) 18 (8)
SEPS1 5227 
rs4965373
GG 71 (46) 74 (48) 150 (55) 34 (42) 92 (51) 89 (53) 74 (51) 102 (46)
GA 61 (39) 66 (42) 103 (38) 37 (45) 72 (40) 62 (37) 51 (35) 105 (48)
AA 23 (15) 15 (10) 19 (7) 10 (12) 16 (9) 17 (10) 20 (14) 13 (6)
SEPS1 9707 
rs2101171
TT 87 (56) 90 (58) 172 (63) 43 (53) 111 (61) 105 (61) 96 (64) 124 (55)
TC 55 (36) 58 (37) 91 (34) 36 (44) 64 (35) 56 (33) 40 (27) 95 (43)
CC 13 (8) 7 (5) 9 (3) 2 (3) 6 (3) 10 (6) 13 (9) 4 (2)BMC Genomics 2008, 9:329 http://www.biomedcentral.com/1471-2164/9/329
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and healthy individuals were compared. The authors sug-
gested that two polymorphisms contribute to the risk for
coronary heart disease and for ischemic stroke in females;
interestingly, the associated polymorphisms do not corre-
spond with the one at -105G/A [21]. Therefore, evidences
are mounting against the role of the SEPS1 gene in all
these conditions, with the only exception to this point of
one report defining the minor allele at -105G/A SEPS1 as
a risk factor for preeclampsia in a large Norwegian cohort
[26].
Conclusion
The Wellcome Trust Case Control Consortium published
recently a genome wide association study for several
inflammatory conditions, such as RA, T1D or CD [27]
Although the chromosomal region where the gene maps
did not show association for any of the mentioned dis-
eases, the SEPS1 polymorphisms were not analyzed and
therefore their involvement in susceptibility could not be
formally excluded. Ours is a thorough study analyzing the
influence of six polymorphisms along the SEPS1 gene on
susceptibility to common diseases, unravelling lack of
association. Our data allow discardind a major individual
role of this gene in the aetiology of the studied polygenic
diseases.
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